These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 34225008)
1. The estrogen receptor/GATA3/FOXA1 transcriptional network: lessons learned from breast cancer. Martin EM; Orlando KA; Yokobori K; Wade PA Curr Opin Struct Biol; 2021 Dec; 71():65-70. PubMed ID: 34225008 [TBL] [Abstract][Full Text] [Related]
2. Cancer-specific mutation of GATA3 disrupts the transcriptional regulatory network governed by Estrogen Receptor alpha, FOXA1 and GATA3. Takaku M; Grimm SA; De Kumar B; Bennett BD; Wade PA Nucleic Acids Res; 2020 May; 48(9):4756-4768. PubMed ID: 32232341 [TBL] [Abstract][Full Text] [Related]
3. A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells. Lee JY; Park YJ; Oh N; Kwack KB; Park KS Oncotarget; 2017 Jun; 8(26):42752-42760. PubMed ID: 28514748 [TBL] [Abstract][Full Text] [Related]
4. FOXA1 in breast cancer. Nakshatri H; Badve S Expert Rev Mol Med; 2009 Mar; 11():e8. PubMed ID: 19261198 [TBL] [Abstract][Full Text] [Related]
5. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297 [TBL] [Abstract][Full Text] [Related]
6. Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state. Kong SL; Li G; Loh SL; Sung WK; Liu ET Mol Syst Biol; 2011 Aug; 7():526. PubMed ID: 21878914 [TBL] [Abstract][Full Text] [Related]
7. Cooperativity of co-factor NR2F2 with Pioneer Factors GATA3, FOXA1 in promoting ERα function. Jiang G; Wang X; Sheng D; Zhou L; Liu Y; Xu C; Liu S; Zhang J Theranostics; 2019; 9(22):6501-6516. PubMed ID: 31588232 [TBL] [Abstract][Full Text] [Related]
8. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Bernardo GM; Lozada KL; Miedler JD; Harburg G; Hewitt SC; Mosley JD; Godwin AK; Korach KS; Visvader JE; Kaestner KH; Abdul-Karim FW; Montano MM; Keri RA Development; 2010 Jun; 137(12):2045-54. PubMed ID: 20501593 [TBL] [Abstract][Full Text] [Related]
9. NR2F2 Orphan Nuclear Receptor is Involved in Estrogen Receptor Alpha-Mediated Transcriptional Regulation in Luminal A Breast Cancer Cells. Erdős E; Bálint BL Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168782 [TBL] [Abstract][Full Text] [Related]
10. Nonlinear relationship between chromatin accessibility and estradiol-regulated gene expression. Chen D; Parker TM; Bhat-Nakshatri P; Chu X; Liu Y; Wang Y; Nakshatri H Oncogene; 2021 Feb; 40(7):1332-1346. PubMed ID: 33420376 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642 [TBL] [Abstract][Full Text] [Related]
12. A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. Brunner AL; Li J; Guo X; Sweeney RT; Varma S; Zhu SX; Li R; Tibshirani R; West RB Genome Biol; 2014 May; 15(5):R71. PubMed ID: 24887547 [TBL] [Abstract][Full Text] [Related]
13. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945 [TBL] [Abstract][Full Text] [Related]
14. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Theodorou V; Stark R; Menon S; Carroll JS Genome Res; 2013 Jan; 23(1):12-22. PubMed ID: 23172872 [TBL] [Abstract][Full Text] [Related]
15. Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice. Cornelissen LM; Henneman L; Drenth AP; Schut E; de Bruijn R; Klarenbeek S; Zwart W; Jonkers J J Mammary Gland Biol Neoplasia; 2019 Dec; 24(4):305-321. PubMed ID: 31729597 [TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer. Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157 [TBL] [Abstract][Full Text] [Related]
17. Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade. Kumar B; Prasad M; Bhat-Nakshatri P; Anjanappa M; Kalra M; Marino N; Storniolo AM; Rao X; Liu S; Wan J; Liu Y; Nakshatri H Cancer Res; 2018 Sep; 78(17):5107-5123. PubMed ID: 29997232 [TBL] [Abstract][Full Text] [Related]
18. Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival. Byun JS; Singhal SK; Park S; Yi DI; Yan T; Caban A; Jones A; Mukhopadhyay P; Gil SM; Hewitt SM; Newman L; Davis MB; Jenkins BD; Sepulveda JL; De Siervi A; Nápoles AM; Vohra NA; Gardner K Clin Cancer Res; 2020 Apr; 26(8):1905-1914. PubMed ID: 31911546 [TBL] [Abstract][Full Text] [Related]
19. Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Eeckhoute J; Keeton EK; Lupien M; Krum SA; Carroll JS; Brown M Cancer Res; 2007 Jul; 67(13):6477-83. PubMed ID: 17616709 [TBL] [Abstract][Full Text] [Related]
20. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype. Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]